Business Wire

TX-FLUENCE

14.7.2022 15:02:08 CEST | Business Wire | Press release

Share
Fluence and BioLumic Partner to Bring Advanced UV Light Treatments to Global Cultivation Facilities

Fluence , a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and food production, announced today its exclusive partnership with BioLumic , a plant-growth biotechnology company that harnesses the power of ultraviolet (UV) light to sustainably increase plant yields, health and quality with Light Signal Recipes™. Under the agreement, Fluence and BioLumic will collaborate to deliver BioLumic’s cutting-edge UV Light Signals through Fluence’s industry-leading LED lighting solutions.

BioLumic’s patented technology leverages UV photomorphogenesis to trigger biological events in seeds and young plants to dramatically optimize plant performance. The company’s proven UV Light Signal Recipes™ can induce large gains in plant yields, desirable plant traits and vigor while also activating natural plant resistance to disease and pests.

“Our goal at Fluence is to drive cutting-edge plant science and innovations in agriculture technology,” said David Cohen, CEO of Fluence. “We’re excited to pursue that goal in collaboration with BioLumic and create the next generation of leading lighting solutions for cannabis and produce growers around the world.”

Fluence’s lighting systems will deliver BioLumic’s dynamic UV light treatments in the propagation phase of plant production—one-time treatments that trigger benefits that accrue through the entire plant growth cycle. Pairing BioLumic and Fluence’s leading market solutions enables cultivators to achieve high-quality yield gains, enhance cannabinoid levels and improve overall plant quality while reducing cycle-to-cycle variability.

“BioLumic’s Light Signal Recipes™ allow cultivators to fully and frictionlessly harness UV lighting to improve plant growth and genetic expression without big input costs or chemicals,” said Steve Sibulkin, CEO of BioLumic. “This partnership will accelerate the development of BioLumic’s Light Signal Platform, increase our company’s access to the global horticulture market and strengthen Fluence’s horticultural lighting portfolio. It’s a tremendous win for growers looking for new ways to grow more with less.”

The partnership reinforces Fluence’s deep history of science-led innovation in photobiology and follows several product launches this year, including RAPTR, RAZR Modular System, VYNE, SPYDR Fang, SPYDR 2h and Wireless Flex Dimming. Fluence’s dynamic and expanding suite of luminaires and lighting controls empowers growers with advanced lighting technology that meets and exceeds cultivation goals.

Fluence and BioLumic will initially work with select cannabis cultivation partners while industrializing commercial delivery systems for UV light that enhance Fluence’s end-to-end product offering in 2023. For more information about BioLumic, please visit www.biolumic.com . For more information about Fluence, visit www.fluence.science .

About Fluence

Fluence Bioengineering, Inc. (Fluence) creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis market and is committed to enabling more efficient crop production with the world’s top vertical farms and greenhouse produce growers. Fluence global headquarters are in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. Fluence operates as a business unit within Signify’s Digital Solutions division. For more information about Fluence, visit www.fluence.science .

About BioLumic

BioLumic is an agricultural biotech company that programs plants with light to unlock growth, quality and disease-resistance. The company's Light Signal Recipe™ platform combines biological insights and genetic marker knowledge to mediate genetic expression with a one-time application of light signals. These treatments are scalable and require no chemical application, genetic modification, facility expansion or large input costs. BioLumic has worked with 12 crops, including cannabis, soybeans, corn, leafy greens and strawberries. In cannabis, the company has helped cultivators produce large double-digit gains in dry flower yield, THC concentration, minor cannabinoids and terpene expression. To learn more, visit www.biolumic.com or send an email to info@biolumic.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SLB Launches ExaCT Electrical Downhole CT Control System24.8.2026 13:02:00 CEST | Press release

New platform brings real-time electrical control to coiled tubing intervention, enabling greater precision, visibility and efficiency across intervention operations SLB (NYSE: SLB) today launched the ExaCT™ electrical downhole coiled tubing (CT) control system, an advanced intervention platform that introduces real-time electrical control to coiled tubing operations. By replacing pressure-dependent hydraulic actuation with electrical communication, power delivery and telemetry, the ExaCT system gives operators greater visibility, precision and control, helping improve intervention execution and reservoir access. The ExaCT system combines electrical power, telemetry and downhole measurements to enable communication with, actuation of and verification of downhole tools throughout an intervention. Continuous communication across the toolstring enables on-demand tool actuation across a wide range of intervention applications, including extended-reach and multilateral wells. The increased p

Wolters Kluwer Transforms Trusted Legal Content Into Structured, AI-Ready Intelligence That Powers the Next Wave of Legal AI24.8.2026 13:01:00 CEST | Press release

By transforming authoritative legal content into structured legal intelligence, Wolters Kluwer gives AI the context and relationships needed to deliver deeper research and higher-quality results Wolters KluwerLegal & Regulatory today announced the next evolution of Libra by Wolters Kluwer, its all-in-one Legal AI Workspace. By transforming authoritative legal sources, expert commentaries, and practical guidance into structured legal intelligence, Wolters Kluwer is making the relationships across the full breadth of its expert legal sources more explicit. This will enable deeper contextual research, more comprehensible answers, and workflow-ready results across legal work. Following the integration of Wolters Kluwer content into the Libra AI workspace in the first half of 2026, laws, rulings, expert commentaries, and practical guidance will now be linked to one another and to the matter at hand, creating a connected knowledge graph of expert-curated and authoredlegal knowledge that AI c

Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization24.8.2026 10:00:00 CEST | Press release

Daiichi Sankyo (TSE: 4568) today announced the appointment of Markus Kosch, MD, as Head of Europe Business, effective April 1, 2027. In this role, he will lead the company's European business within the new globally integrated Commercialization Unit and serve as General Manager of Daiichi Sankyo Europe GmbH, with legal responsibility for the company in Europe. The appointment reflects the next phase of growth of Daiichi Sankyo under its Five-Year Business Plan and the establishment of a new Commercialization Unit. Within this new structure, Markus Kosch will bring together the Oncology and Specialty businesses in Europe under one integrated leadership model to help bring innovative medicines to more patients across the region. For the past five years, Markus Kosch has led the Daiichi Sankyo Oncology Business Division in Europe and Canada, overseeing a period of significant growth and preparing the organization for an increasingly expanding oncology portfolio. Prior to joining Daiichi S

European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union24.8.2026 09:01:00 CEST | Press release

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older, making it the first and only treatment approved for Rett syndrome in the European Union (EU). “The approval of DAYBU marks a significant milestone for the Rett syndrome community in the EU and advances our mission to bring this innovative treatment to patients and families who have long faced a profound unmet medical need,” said Catherine Owen Adams, Acadia’s Chief Executive Officer. “For people living with Rett syndrome, a devastating rare neurodevelopmental disorder, there have been no approved treatment options in the EU. We are proud to make DAYBU available and look forward to supporting patients, caregivers, and healthcare providers gain access to treatment." The DAYBU marketing authorization in the EU is prim

ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 124.8.2026 08:36:00 CEST | Press release

Discovered by Takeda in Japan, ORZEYFUL has the Potential to Redefine Care Beyond Individual Symptom Management for Adults Living with Narcolepsy Type 1 (NT1) Landmark Phase 3 Studies Demonstrated Significant and Meaningful Improvements Across the Full Range of NT1 Symptoms Evaluated in Clinical Trials Compared to Placebo Milestone Marks Third Major Regulatory Approval Secured for ORZEYFUL Around the World Takeda (TOKYO:4502/NYSE:TAK) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the use of ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. ORZEYFUL is a first-in-class oral orexin receptor 2 (OX2R) agonist and the only medicine indicated in Japan to treat the disease holistically rather than individual symptoms. The discovery of this new class of medicine originated in Takeda's laboratories in Japan. Takeda is proceeding with launch preparations and expects to make ORZEYFUL available as quickly

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye